Investigation of a New Rectal Catheter for Users of Transanal Irrigation
The clinical investigation is an exploratory, randomised controlled, open-labelled, crossover investigation.
The clinical investigation will be conducted as a multi-centre clinical investigation in two different clinical investigation sites in Denmark.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Michel Briand de Crevecoeur
- Phone Number: 49111272
- Email: dkmibc@coloplast.com
Study Contact Backup
- Name: Sofie Boll
- Phone Number: 49111640
- Email: dksolb@coloplast.com
Study Locations
-
-
Jutland
-
Århus, Jutland, Denmark, 8200
- Århus Universitetshospital
-
-
Zealand
-
Hvidovre, Zealand, Denmark, 2650
- Amager Hvidovre Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Has given written Informed Consent
- Is at least 18 years old
- Has full legal capacity
- Has used Trans Anal Irrigation (TAI) with balloon catheter for at least 4 weeks prior to inclusion
- Performs TAI minimum 3 times/week
- Is able to follow study procedures assessed by investigator
Exclusion Criteria:
- Has known anal or colorectal stenosis
- Has active/recurrent colorectal cancer
- Is within 3 months of anal or colorectal surgery
- Is within 4 weeks of endoscopic polypectomy
- Has ischaemic colitis
- Has acute inflammatory bowel disease
- Has acute diverticulitis
- Is participating in any other clinical study that may interfere with this study (assessed by investigator).
- Is pregnant or breastfeeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Investigational device - newly developed TAI catheter.
CP362 Test Catheter: The investigational device is intended to perform TAI procedures together with the CE-marked Peristeen® Plus TAI system.
|
The investigational device is intended to perform TAI procedures together with the CE-marked Peristeen Plus TAI system.
|
|
No Intervention: Peristeen Plus
Comparator catheter: The Peristeen® Plus rectal balloon catheter is used together with the CE-marked Peristeen® Plus TAI system.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Was it Possible to Perform Transanal Irrigation?
Time Frame: Evaluated at Visit 1 and Visit 2 (within a time duration of up to 17 days)
|
After visit 1 and visit 2, the primary endpoint, defined as if it was possible to perform transanal irrigation, was answered by a yes/no answer.
|
Evaluated at Visit 1 and Visit 2 (within a time duration of up to 17 days)
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- CP362
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.